Frequency of UTI amongst patients taking SGLT 2 inhibitors
DOI:
https://doi.org/10.48047/7w7d9730Keywords:
Frequency; UTI; SGLT 2 inhibitorsAbstract
Background: SGLT-2 inhibitors are potent anti-hyperglycemic medicines that increase renal glucose excretion and enhance glycemic control. Concerns have been raised about an increased incidence of urinary tract infections in individuals who use these drugs.
Objective: The aim of this study was to find out the frequency of UTI amongst patients taking SGLT 2 inhibitors.
Material and method: The current cross sectional study was carried out at the department of medicine Ghulamm Muhammad Mahar medical college sukkur from January 2024 to June 2024 after taking permission from the ethical board of the institute. Participants of the study provided written informed permission. A total of 130 Individuals with type 2 diabetes of both genders and different age groups who were treated with sodium-glucose cotransporter-2 inhibitors alone or in combination with other drugs were included. Participants were instructed to collect midstream urine samples in a sterile the tube for microbiological analysis. A questionnaire was devised to collect patient history and demographic data. Data was entered and analyzed using SPSS version 25. Quantitative variables such as age were presented as mean ± SD. Qualitative factors such as gender, family history of diabetes, duration of diabetes, symptoms, and frequency of UTIs were provided as percentages. The Chi-square test was performed to evaluate the relationship between UTI, SGL T2 inhibitors, and other factors. P-values < 0.05 were considered significant.
Results: A total of 130 individuals were enrolled in the current study out of which 60 (46.1%) were male and 70(53.8%) were females. out of the total individuals, 27 (20.7%) used Empagliflozin, whereas 103 (79.2%) took Dapagliflozin. In males 4(6.6%) had UTI while in females 10(14%) had urinary tract infection. Of 52(40%) diabetic individuals with a family history of diabetes, 10(19%)7, experienced a urinary tract infection. Among individuals with diabetes for 6-10 years, 3 (9%) experienced UTI. Among individuals with diabetes for more than ten years, four (23%) experienced UTI. Among 27(20.7%) diabetic patients on Empagliflozin, 4(14.8%) experienced urinary tract infection and those receiving Dapagliflozin,10(9.7%) experienced urinary tract infections
Conclusion: The present study evaluated that 10% of diabetes individuals taking SGLT 2 inhibitors experienced urinary tract infections. More research is needed to determine the prevalence of UTIs in diabetes people.
Downloads
References
International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation; 2019.
Basit A, Fawwad A, Qureshi H, Shera AS. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016–2017. BMJ Open. 2018; 8:e020961.
Pelletier R, Ng K, Alkabbani W, et al. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther Adv Drug Saf. 2021; 12:2042098621989134
Chandrashekar M, Philip S, Nesbitt A, et al. Sodium glucose-linked transport protein 2 inhibitors: an overview of genitourinary and perioperative implications. Int J Urol. 2021;28(10):984–90.
Kaze AD, Zhuo M, Kim SC, et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022;21:47.
Ashfaq M, Shafique S, Niazi Z, et al. Occurrence of urinary tract infections in type 2 diabetes mellitus patients taking sodiumglucose co-transporter-2 inhibitors to regulate their blood sugar levels. Int J Health Sci. 2023;7(S1):1999–2005.
.Tanrıverdi M, Baştemir M, Demirbakan H, et al. Association of SGLT -2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocr Disord. 2023;23(1):211.
FREQUENCY OF URINARY TRACT INFECTIONS IN TYPE 2 DIABETES MELLITUS PATIENTS, USING SGLT-2 INHIBITORS. J Popul Ther Clin Pharmacol. 2024;31(3):2424 –29.
S h r i k r i s h n a A, Ar c h a n a B. P r e v a l e n c e o f genitourinary infection in diabetic patients treated with SGL T 2 inhibitors. Afri Health Sci. 2023; 23(1): 270-5
.Khan S, Hashmi MS, Rana MA, Zafar GM, Asif S, Farooq MT , et al. Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin. Cureus. 2022; 14(1): e21720
Hussain M, Hussain A, Rehman HU, Iqbal J. Prevalence of genitourinary infections with sodium glucose cotransporter-2 (SGL T2) inhibitors in patients with type 2 diabetes. Pak J Med Health Sci. 2021; 15(10): 2804-7
Azhar M, Hanif M, Rafi S, Ziauddin M, Sohail N, Kumar R. Frequency of urinary tract infections in type 2 diabetes pat i ent s t aki ng sodi um-gl ucose cot ranspor t er -2 (SGL T2) inhibitors to regulate their blood sugar level. J Pharm Neg Results. 2023; 14(4): 95-99
Caro MKC, Cunanan EC, Kho SA. Incidence and factors associated with genitourinary infections among T ype 2 diabetes patients on SGL T2 Inhibitors: a single retrospective cohort study. Diabetes Epidemiol Manag. 2022; doi: 10.1016/j.deman.2022. 100082
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
